Free Trial
OTCMKTS:OTLC

Oncotelic Therapeutics (OTLC) Stock Price, News & Analysis

Oncotelic Therapeutics logo
$0.06 0.00 (-2.69%)
As of 03:52 PM Eastern

About Oncotelic Therapeutics Stock (OTCMKTS:OTLC)

Key Stats

Today's Range
$0.05
$0.06
50-Day Range
$0.03
$0.07
52-Week Range
$0.02
$0.07
Volume
48,000 shs
Average Volume
137,779 shs
Market Capitalization
$23.58 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Oncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-ß2, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus. It also develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; and CA4P for the treatment of advanced metastatic melanoma; intranasal drug and delivery system for intra-nasal Apomorphine for the treatment of Parkinson's Disease, erectile disfunction, and female sexual disfunction; Artemisinin, a natural derivative from an Asian herb Artemisia Annua; and AI based technologies to enhance the development and commercialization of Artemisinin based products and support technologies. Oncotelic Therapeutics, Inc. is based in Agoura Hills, California.

Oncotelic Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
7th Percentile Overall Score

OTLC MarketRank™: 

Oncotelic Therapeutics scored higher than 7% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Oncotelic Therapeutics.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Oncotelic Therapeutics is -5.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Oncotelic Therapeutics is -5.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Oncotelic Therapeutics has a P/B Ratio of 1.93. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    0.03% of the float of Oncotelic Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Oncotelic Therapeutics has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Oncotelic Therapeutics has recently increased by 307.79%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Oncotelic Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Oncotelic Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.03% of the float of Oncotelic Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Oncotelic Therapeutics has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Oncotelic Therapeutics has recently increased by 307.79%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Oncotelic Therapeutics has a news sentiment score of -0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.85 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Oncotelic Therapeutics this week, compared to 0 articles on an average week.
  • Search Interest

    Only 1 people have searched for OTLC on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Oncotelic Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    39.22% of the stock of Oncotelic Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Read more about Oncotelic Therapeutics' insider trading history.
Receive OTLC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oncotelic Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

OTLC Stock News Headlines

The Trump Dump is starting; Get out of stocks now?
The first 365 days of the Trump presidency… Will be the best time to get rich in American history.
Oncotelic Therapeutics Inc (OTLC)
See More Headlines

OTLC Stock Analysis - Frequently Asked Questions

Oncotelic Therapeutics' stock was trading at $0.0350 on January 1st, 2025. Since then, OTLC shares have increased by 65.4% and is now trading at $0.0579.
View the best growth stocks for 2025 here
.

Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) announced its quarterly earnings data on Thursday, August, 19th. The company reported ($0.01) earnings per share for the quarter, topping analysts' consensus estimates of ($0.03) by $0.02.

Shares of OTLC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Oncotelic Therapeutics investors own include MariMed (MRMD), First Wave BioPharma (FWBI), DSS (DSS), CEMEX (CX), CohBar (CWBR), ContraFect (CFRX) and Avid Bioservices (CDMO).

Company Calendar

Last Earnings
8/19/2021
Today
4/29/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
OTCMKTS:OTLC
Employees
20
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-7,900,000.00
Pretax Margin
-2,147.14%

Debt

Sales & Book Value

Annual Sales
$70,000.00
Cash Flow
$0.02 per share
Price / Cash Flow
3.12
Book Value
$0.03 per share
Price / Book
1.98

Miscellaneous

Free Float
246,931,000
Market Cap
$24.23 million
Optionable
Not Optionable
Beta
-0.69
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

This page (OTCMKTS:OTLC) was last updated on 4/29/2025 by MarketBeat.com Staff
From Our Partners